DUNDEE, Scotland, November 21, 2017 /PRNewswire/ --
Vascular Flow Technologies, the medical device company who
developed the proprietary Spiral Laminar Flow (SLF ™) technology to
re-establish natural blood flow for enhanced patient outcomes,
today announces the successful conclusion of a strategic
intellectual property out-licencing agreement with Biovic Sdn
bhd.
Biovic are a Malaysian based high tech biomedical company
focussed on meeting the needs of patients in developing medical
communities with high quality, transformational products. Biovic's
long term strategic plans are to become a globally competitive
biomedical device company with sales into the US and other
developed markets.
This strategic partnership will see VFT's Spiral Laminar Flow
(SLF™) technology used to enhance Biovic's existing AVATAR® ePTFE
Vascular Graft. VFT's SLF™ technology is a unique and IP protected
design which eliminates the turbulent blood flow seen in diseased
vessels and standard prosthetic vascular grafts. By reintroducing
the normal pattern of blood flow through the vessel, graft failure
and complications for the patient are significantly reduced. The
technology is built on an extensive base of evidence produced using
CFD (models of fluid flow created with numerical analysis) and FEA
(virtual modelling to problem solve potential stresses on vessel
walls).
Craig Dunlop, General Manager of
Vascular Flow Technologies, commented: "This is a very
exciting opportunity for VFT and Biovic. Combining the superior
clinical performance of VFT's SLF™ technology with a
high performance ePTFE graft, will disrupt the
existing market with an enhanced ePTFE
Vascular graft with unique new features and
patient benefits."
VFT and Biovic will collaborate closely over the coming months
to bring the Avatar SLF™ graft to the market by Q2 2018.
This agreement underpins and validates VFT's revised business
model of collaborative SLF™ product development across multiple
treatment areas including Peripheral Stents, Hybrid Stent Grafts
and Haemodialysis Catheters. VFT continues to work with the key
players in these sectors to apply SLF technology to existing
products thereby addressing unmet patient and clinical needs. VFT's
diverse new product pipeline is supported by 18 strong patent
families.
About Vascular Flow Technologies
Vascular Flow Technologies is a leading innovator focused on the
research and development of proprietary platform technology to
improve blood flow in compromised or diseased blood vessels. Its
patented Spiral Laminar Flow™ (SLF™ ) technology is the only
clinically-proven design to replicate the distinctive singular
spiral flow pattern of natural blood flow. The SLF™ technology is
used to create a longer lasting graft or stent, producing a better
quality of life for the patient due to reduced vascular
complications and improved longevity of the implant. VFT is a
privately held company with headquarters in Dundee, UK. Further information is available
at http://www.vascular-flow.com.
About Spiral Laminar Flow
Turbulent blood flow at the point where an endovascular implant
joins with the blood vessel is a major cause of neointimal
hyperplasia (excessive cell growth) which can result in vessel
blockage. Spiral Laminar Flow™ technology generates a spiral flow
within the implant, reducing turbulence distally and in the case of
bypass and AV access grafts has shown significant improvements in
outcomes. Vascular Flow Technologies' SLF™ technology is supported
by numerous clinical studies and a significant patent array.
For more information, please contact
Craig Dunlop - General Manager, Vascular Flow
Technologies
T: +44(0)1382-562797
E: craig.dunlop@vascular-flow.com
W: http://www.vascular-flow.com